2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Thrombocytopenia
14
Leukemia, Myeloid, Acute
11
Leukemia
7
Myelodysplastic Syndromes
5
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Jacobs syndrome
3
Sarcoma
2
Purpura, Thrombocytopenic, Idiopathic
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Hematologic Neoplasms
2
Congenital Abnormalities
2
Solid Tumor, Childhood
1
Recurrence
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
eltrombopag
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts